The investment will allow the company to enter the production phase of its first-of-its-kind, natural and sustainable active ingredients as well as expand the pipeline of products. Using cutting-edge biotechnology and proprietary R&D tools and insights, the company is developing first-of-its-kind precision fermentation processes to replace fossil-based alternatives. The company today has several commercial partnerships, including collaborations with large market players such as Givaudan and WACKER. Biosyntia is an industrial biotech company delivering nature’s ingredients at scale both affordably and sustainably.